Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis
- PMID: 24525528
- DOI: 10.1159/000356755
Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis
Abstract
Background: In recent years, multidrug-resistant Acinetobacter baumannii has been reported as an important nosocomial pathogen, and treatment options are limited. The aim of this study was to investigate the additional effect of sulbactam on monotherapy with colistin, tigecycline and imipenem in experimental sepsis with carbapenem-resistant A. baumannii in mice.
Methods: Sepsis was developed in 8- to 10-week-old BALB/c mice by an intraperitoneal injection of A. baumannii. Antibiotic was given intraperitoneally 2 h after bacterial inoculation. Each experimental group had 15 mice and was divided into 3 subgroups. Mice were sacrificed at 24, 48 or 72 h. Lung, liver, heart and spleen samples were cultured, and homogenates of lung and liver were used to detect the number of colony-forming units per gram. Bacterial clearance was compared in lung and liver at different time points.
Results: Imipenem did not decrease the bacterial load, but the other antibiotics showed significant bactericidal activity compared with the control group, and the combination of imipenem with sulbactam decreased the bacterial load in lung and liver. However, the addition of sulbactam to colistin and tigecycline had no significant effect on bacterial counts. Only the addition of sulbactam to imipenem showed better bactericidal activity compared to imipenem alone.
Conclusions: These results suggested that combining sulbactam with tigeycline or colistin does not increase the efficiency of these antibiotics.
Similar articles
-
Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii.New Microbiol. 2015 Jan;38(1):67-73. Epub 2015 Jan 1. New Microbiol. 2015. PMID: 25742149
-
In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.J Antimicrob Chemother. 2007 Aug;60(2):317-22. doi: 10.1093/jac/dkm136. Epub 2007 May 31. J Antimicrob Chemother. 2007. PMID: 17540672
-
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172. J Int Med Res. 2013. PMID: 24265334
-
Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Expert Rev Anti Infect Ther. 2015 Jun;13(6):769-77. doi: 10.1586/14787210.2015.1032254. Epub 2015 Apr 12. Expert Rev Anti Infect Ther. 2015. PMID: 25865094 Review.
-
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis.J Glob Antimicrob Resist. 2021 Mar;24:136-147. doi: 10.1016/j.jgar.2020.08.021. Epub 2020 Sep 2. J Glob Antimicrob Resist. 2021. PMID: 32889142 Review.
Cited by
-
Colistin potentiation in multidrug-resistant Acinetobacter baumannii by a non-cytotoxic guanidine derivative of silver.Front Microbiol. 2023 Jan 4;13:1006604. doi: 10.3389/fmicb.2022.1006604. eCollection 2022. Front Microbiol. 2023. PMID: 36687622 Free PMC article.
-
Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility.Microbiol Spectr. 2022 Jun 29;10(3):e0054222. doi: 10.1128/spectrum.00542-22. Epub 2022 Jun 1. Microbiol Spectr. 2022. PMID: 35647655 Free PMC article.
-
The investigation of adrenal involvement in carbapenem resistant Acinetobacter baumannii sepsis: experimental mouse model.Turk J Med Sci. 2021 Dec 13;51(6):3108-3114. doi: 10.3906/sag-2001-163. Turk J Med Sci. 2021. PMID: 34493028 Free PMC article.
-
Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?Antibiotics (Basel). 2021 May 28;10(6):646. doi: 10.3390/antibiotics10060646. Antibiotics (Basel). 2021. PMID: 34071451 Free PMC article. Review.
-
Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy.J Microbiol. 2017 Nov;55(11):837-849. doi: 10.1007/s12275-017-7288-4. Epub 2017 Oct 27. J Microbiol. 2017. PMID: 29076065 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical